Name: Latest research reports of Glenmark Pharmaceuticals Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Glenmark Pharmaceuticals Ltd.
Rating: 5
Author: ICICI Securities Limited

Glenmark Pharmaceuticals Ltd.

NSE: GLENMARK | BSE: 532296 | ISIN: INE935A01035 | Industry: Pharmaceuticals
| Strong Performer, Getting Expensive

2130.9000 14.60 (0.69%)

NSE Sep 10, 2025 15:31 PM

67.06% Gain from 52W Low

Volume: 773.7K

Glenmark Pharmaceuticals Ltd.

03 Feb 2017

2130.90

0.69%

Glenmark Pharmaceuticals

Buy: Glenmark Pharmaceuticals Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 43% YoY to | 2535 crore (I-direct estimate: | 2239 crore) mainly due to 102% YoY growth in the US to | 1231 crore (Idirect estimate: | 865 crore) mainly due to gZetia exclusivity EBITDA margins improved 934 bps YoY to 30.2% (I-direct estimate:...

Glenmark Pharmaceuti.. has an average target of 2144.00 from 5 brokers.